New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:48 EDTABT, PCYCPharmacyclics shares have 90% upside potential, says Deutsche Bank
Deutsche Bank believes shares of Pharmacyclics (PCYC) have 90% upside potential over the next 12 months following the recent pullback. Deutsche attributes to the recent pullback to fears around Abbott's (ABT) data for ABT199 at ASCO and weekly scripts that came in lower than some investor expectations. The firm has a Buy rating on Pharmacyclics with a $180 price target.
News For PCYC;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
09:24 EDTABTAbbott says on track for another year of double digit adjusted EPS growth
Subscribe for More Information
09:21 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
09:16 EDTABTAbbott sees Q4 reported sales growth in high single digits
Subscribe for More Information
09:14 EDTABTAbbott sees FY14 operational sales growth in the mid single digits
Sees foreign exchange to have negative impact of approx. 2% on FY reported sales, somewhat more negative than previous expectations. Sees FY14 reported sales growth in low to mid single digits. Sees FY gross margin ratio about 55% of sales. Comments made on the Q3 earnings conference call.
08:04 EDTABTAbbott raises FY14 adjusted EPS view to $2.25-$2.27 from $2.19-$2.29
Subscribe for More Information
07:37 EDTABTAbbott sees Q4 EPS excl items 68c-70c, consensus 70c
Subscribe for More Information
07:36 EDTABTAbbott reports Q3 Nutrition revenue $1.79B, Q3 Diagnostics revenue $1.19B
Subscribe for More Information
07:34 EDTABTAbbott reports Q3 EPS 62c, consensus 59c
Subscribe for More Information
October 21, 2014
15:35 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
08:14 EDTPCYCPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
08:57 EDTPCYCPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTPCYCPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:34 EDTPCYCPharmacyclics management to meet with JPMorgan
Subscribe for More Information
October 16, 2014
14:47 EDTPCYCRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
October 15, 2014
10:48 EDTABTShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
06:16 EDTPCYCPharmacyclics initiated with a Buy at Citigroup
Subscribe for More Information
October 13, 2014
08:05 EDTPCYCBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use